Company: CPMV
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001683168-25-006318
Chunk: 5

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-08-19
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
 used in operating activities: 

    Share-based compensation 
     –  
     4,867 
  
    Non-cash interest on convertible notes 
     36,365  
     36,565 
  
    Interest expense on loan payable 
     –  
     1,133 
  
    Accretion to redemption value on convertible notes 
     –  
     1,446 
  
    Changes in operating assets and liabilities: 

    Prepaid expenses and other current assets 
     22,476  
     14,812 
  
    Accounts payable 
     (1,057) 
     6,562 
  
    Accrued compensation 
     244,346  
     327,566 
  
    Accrued expenses and other 
     (10,218) 
     (18,186)
  
    Net cash used in operating activities 
     (61,436) 
     (207,444)

    Financing activities: 

    Proceeds from issuance of loan payable 
     –  
     55,000 
  
    Net cash provided by financing activities 
     –  
     55,000 

    Net change in cash and cash equivalents 
     (61,436) 
     (152,444)

    Cash and cash equivalents, beginning of period 
     115,019  
     156,178 

    Cash and cash equivalents, end of period 
    $53,583  
    $3,734 

    Supplemental disclosure of cash flow information: 

    Cash paid for income taxes 
    $2,400  
    $– 
  
    Cash paid for interest 
    $–  
    $– 

See accompanying notes
to unaudited condensed consolidated financial statements.

 7 

    Mosaic ImmunoEngineering, Inc.

    Notes to Unaudited Condensed Consolidated Financial Statements
    For the Three and Six Months Ended June 30, 2025

Unless the context otherwise requires, references
to the “Company,” the “combined company,” “Mosaic,” “we,” “our,” or “us”
in this Quarterly Report on Form 10-Q ("Report" or “Quarterly Report”) refer to Mosaic ImmunoEngineering, Inc. and
its subsidiaries.

    1.
    Organization and Business

Organization

Mosaic ImmunoEngineering, Inc.